Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the best length of prednisone treatment for patients with granulomatosis with polyangiitis GPA and microscopic polyangiitis MPA, serious autoimmune diseases that can relapse and cause damage despite current treatments. Rituximab is commonly used to maintain remission, but the ideal duration for prednisone therapy remains unclear. This trial is the first prospective study to compare longer versus shorter prednisone use as an add-on to remission maintenance in these conditions. Participants will receive either prednisone 5 mg per day or a placebo for 12 months, with dosing beginning on Day 1. Prednisone dosage will be tapered by 1 mg per week until complete withdrawal after 12 months. The study is randomized, double-blind, and placebo-controlled, evaluating the impact of extended prednisone use alongside rituximab maintenance therapy. During the 30-month study period, participants will be monitored for relapse-free survival, defined by a disease activity score BVAS greater than zero. Researchers will also assess serious adverse events, glucocorticoid-related complications like fractures and weight gain, vasculitis relapse rates, prednisone use, bone density, disease damage, functional disability, quality of life, and healthcare resource use. Assessments include clinical evaluations and standardized questionnaires to track disease status and treatment effects over time.
Actively Recruiting
Researchers are evaluating whether a personalized rehabilitation program that combines nutrition, physiotherapy, and physical activity, started early in the intensive care unit ICU and continued through hospital discharge and at home, can improve long-term outcomes for patients who have undergone invasive mechanical ventilation and vasopressor therapy. This trial compares this early extended rehabilitation approach to usual care, which involves standard nutritional support and physiotherapy provided according to local ICU practices. Participants will be randomly assigned to either the individualized rehabilitation group or the usual care group. The rehabilitation group will receive a tailored program involving dieticians, physiotherapists, and physical activity instructors, with the intervention continuing for 12 weeks from ICU admission through post-ICU wards and at home. The usual care group will receive standard nutritional and physiotherapy support from day 0 to day 180. Throughout the study, participants will undergo various assessments including physical activity levels, muscle strength, muscle mass, body weight, and quality of life measured at multiple time points up to 12 months after randomization. The primary outcome is the distance walked in six minutes at 6 months. Researchers will also track mortality rates, glucose control, insulin usage, infection rates, and hospital stay lengths. The total participation may last up to 12 months with follow-up evaluations during this period.
Actively Recruiting
Researchers are studying patients with chronic obstructive pulmonary disease COPD who experience frequent exacerbations. The study aims to compare the effectiveness of remote monitoring using the Bora Care solution versus conventional follow-up care. The main goal is to see if remote monitoring reduces the total number of hospital days due to respiratory problems over one year. Participants are randomly assigned to either a control group or an experimental group. The control group receives conventional care, including two general practitioner visits and one pulmonologist visit per year. The experimental group receives the same conventional care plus the Bora Care remote monitoring system, which includes a wristband that measures vital signs at home, a platform for caregivers to view data, and an early detection score for COPD exacerbations. Nurses trained in the Bora Care system monitor patients daily, alert the pulmonologist if needed, and follow up on any alerts. During the study, participants will have clinical visits including a 12-month follow-up with a pulmonologist. Researchers will monitor hospitalizations, length of hospital stays, quality of life, device usage, care organization, and patient and caregiver satisfaction over one to three years. The study uses a randomized design without masking and will last until December 2027.